Cooper Companies (NYSE:COO) Now Covered by KeyCorp

Equities researchers at KeyCorp started coverage on shares of Cooper Companies (NYSE:COOGet Free Report) in a research report issued on Tuesday, Benzinga reports. The brokerage set a “sector weight” rating on the medical device company’s stock. KeyCorp also issued estimates for Cooper Companies’ Q1 2024 earnings at $3.10 EPS, Q2 2024 earnings at $3.14 EPS, Q3 2024 earnings at $3.69 EPS and Q4 2024 earnings at $3.86 EPS.

Several other research firms have also recently commented on COO. Morgan Stanley dropped their target price on shares of Cooper Companies from $410.00 to $355.00 and set an “equal weight” rating on the stock in a research report on Monday, December 4th. TheStreet raised shares of Cooper Companies from a “c+” rating to a “b-” rating in a research report on Thursday, January 11th. Piper Sandler raised their price target on shares of Cooper Companies from $430.00 to $440.00 and gave the stock an “overweight” rating in a research note on Friday, January 12th. Bank of America began coverage on shares of Cooper Companies in a research note on Monday, October 30th. They set a “buy” rating and a $380.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Cooper Companies from $385.00 to $375.00 and set a “neutral” rating for the company in a research note on Wednesday, November 29th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $401.30.

Get Our Latest Stock Analysis on Cooper Companies

Cooper Companies Price Performance

Shares of NYSE COO opened at $374.64 on Tuesday. Cooper Companies has a fifty-two week low of $303.74 and a fifty-two week high of $399.62. The stock has a market cap of $18.62 billion, a price-to-earnings ratio of 63.39, a PEG ratio of 2.46 and a beta of 0.94. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.00 and a current ratio of 1.76. The firm’s 50-day simple moving average is $368.66 and its 200 day simple moving average is $353.81.

Cooper Companies shares are set to split on the morning of Tuesday, February 20th. The 4-1 split was announced on Tuesday, February 20th. The newly created shares will be distributed to shareholders after the market closes on Tuesday, February 20th.

Cooper Companies (NYSE:COOGet Free Report) last announced its quarterly earnings results on Thursday, December 7th. The medical device company reported $3.47 earnings per share for the quarter, missing the consensus estimate of $3.48 by ($0.01). Cooper Companies had a net margin of 8.19% and a return on equity of 8.56%. The business had revenue of $927.10 million during the quarter, compared to the consensus estimate of $924.57 million. During the same period in the previous year, the business posted $2.75 EPS. Cooper Companies’s revenue was up 9.3% compared to the same quarter last year. As a group, research analysts anticipate that Cooper Companies will post 13.82 earnings per share for the current fiscal year.

Insider Activity at Cooper Companies

In related news, Director Robert S. Weiss sold 79,370 shares of Cooper Companies stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $364.81, for a total value of $28,954,969.70. Following the completion of the transaction, the director now directly owns 70,693 shares in the company, valued at approximately $25,789,513.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Cooper Companies news, Director Robert S. Weiss sold 79,370 shares of the firm’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $364.81, for a total value of $28,954,969.70. Following the completion of the transaction, the director now directly owns 70,693 shares of the company’s stock, valued at approximately $25,789,513.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Gary S. Petersmeyer sold 150 shares of the firm’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $336.03, for a total transaction of $50,404.50. Following the completion of the transaction, the director now directly owns 2,297 shares of the company’s stock, valued at $771,860.91. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,820 shares of company stock worth $29,115,939. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Cooper Companies

A number of hedge funds have recently made changes to their positions in COO. Cary Street Partners Investment Advisory LLC bought a new stake in shares of Cooper Companies during the 3rd quarter worth $26,000. KB Financial Partners LLC bought a new stake in shares of Cooper Companies during the 1st quarter worth $34,000. Clear Street Markets LLC lifted its holdings in shares of Cooper Companies by 93.9% during the 1st quarter. Clear Street Markets LLC now owns 95 shares of the medical device company’s stock worth $35,000 after acquiring an additional 46 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Cooper Companies by 54.8% during the 4th quarter. Blue Trust Inc. now owns 96 shares of the medical device company’s stock worth $36,000 after acquiring an additional 34 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in shares of Cooper Companies by 182.5% during the 4th quarter. Lindbrook Capital LLC now owns 113 shares of the medical device company’s stock worth $43,000 after acquiring an additional 73 shares during the last quarter. 96.31% of the stock is owned by institutional investors.

About Cooper Companies

(Get Free Report)

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

Featured Articles

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.